Table 3.

FISH analysis of BCL2, BCL6, C-MYC and IgH gene aberrations

	DLBCL, n=57N (%)	FL, n=15 N (%)	Others, n=9 N (%)
BCL-2
Gain	13 (22.8%)	0	1 (11.1%) *MZL
Translocated	3 (5.3%)	4 (26.7%)	0
Translocated & Gain	0	2 (13.3%)	0
BCL-6
Gain	6 (10.5%)	1 (6.7%)	0
Translocated	10 (17.5%)	3 (20.0%)	0
Translocated & Gain	3 (5.3%)	0	0
C-MYC
Gain	5 (8.8%)	2 (13.3%)	0
Translocated	4 (7.0%)	0	1 (11.1%) *BL
Translocated & Gain	0	0	0
IgH
Gain	1 (1.8%)	0 (0.0%)	0
Translocated	17 (29.8%)	7 (46.7%)	1 (11.1%) *BL
Translocated & Gain	2 (3.5%)	0	0

MZL, Marginal Zone Lymphoma; BL, Burkitt Lymphoma